kcj
Korean Circulation Journal

Original Research

Check for updates

Impact of Non-Vitamin K Antagonist Oral Anticoagulants on the Change of Antithrombotic Regimens in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Soonil Kwon [iD], MD[1,*], Jin-Hyung Jung [iD], MS[2,*], Eue-Keun Choi [iD], MD, PhD[1,3],
Seung-Woo Lee [iD], BSc[4], Jiesuck Park [iD], MD[1], So-Ryoung Lee [iD], MD, PhD[1],
Jeehoon Kang [iD], MD[1], Kyungdo Han [iD], PhD[4], Kyung Woo Park [iD], MD, PhD[1,3],
Seil Oh [iD], MD, PhD[1,3], and Gregory Y. H. Lip [iD], MD[1,3,5,6]

[1]Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
[2]Department of Medical Statistics, College of Medicine, The Catholic University of Korea, Seoul, Korea
[3]Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
[4]Department of Statistics and Actuarial Science, Soongsil University, Seoul, Korea
[5]Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Chest & Heart Hospital, Liverpool, United Kingdom
[6]Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

ORCID iDs
Soonil Kwon [iD]
https://orcid.org/0000-0002-4791-6855
Jin-Hyung Jung [iD]
https://orcid.org/0000-0002-8920-8777
Eue-Keun Choi [iD]
https://orcid.org/0000-0002-0411-6372
Seung-Woo Lee [iD]
https://orcid.org/0000-0003-3389-8219
Jiesuck Park [iD]
https://orcid.org/0000-0001-6924-7106
So-Ryoung Lee [iD]
https://orcid.org/0000-0002-6351-5015
Jeehoon Kang [iD]
https://orcid.org/0000-0002-9078-2231
Kyungdo Han [iD]
https://orcid.org/0000-0002-6096-1263

ABSTRACT

Background and Objectives: Antithrombotic therapy after percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF) has changed in recent years with new data from large randomized trials and updates to clinical guidelines. This study aimed to investigate the trends in periprocedural antithrombotic regimens in Korean patients with AF undergoing PCI with non-vitamin K antagonist oral anticoagulants (NOACs).
Methods: Using the claims database of the Health Insurance Review and Assessment during 2013–2018, 27,594 patients with AF undergoing PCI were identified. The annual prevalence of PCI and prescriptions of each antithrombotic agent, including antiplatelet agents and oral anticoagulants, within 30 days after PCI were investigated.
Results: During 2013–2018, the number of patients with AF undergoing PCI increased up to 1.3-fold (from 3,913 to 5,075 patients per year). After the introduction of NOACs, the proportion of dual antiplatelet therapy (DAPT) decreased from 71.9% to 49.8% but still occupied the largest proportion among antithrombotic regimens. Triple antithrombotic therapy (TAT) use increased from 25.4% to 46.0%, and NOAC has rapidly replaced warfarin as the oral anticoagulant of choice. TAT was preferred to DAPT for patients with CHA_2DS_2-VASc score ≥2. Among various factors, prior intracranial hemorrhage was the most powerful predictor of favoring DAPT use over TAT.
Conclusion: Since the introduction of NOACs, the patterns of periprocedural antithrombotic regimens have changed rapidly toward more use of TAT, specifically with NOAC-based regimen. Appropriate stroke prevention with oral anticoagulants is still underutilized in patients with AF undergoing PCI in Korea.

Keywords: Atrial fibrillation; Percutaneous coronary intervention; Antiplatelet drugs; Anticoagulant drugs

Kyung Woo Park (iD)
https://orcid.org/0000-0003-2432-4432
Seil Oh (iD)
https://orcid.org/0000-0002-2504-9615
Gregory Y. H. Lip (iD)
https://orcid.org/0000-0002-7566-1626

INTRODUCTION

Atrial fibrillation (AF) is the most common cardiac arrhythmia, and stroke prevention with oral anticoagulation (OAC) is central to its management when stroke risk factors are present.[1] With the advent of the non-vitamin K antagonist oral anticoagulants (NOACs), the perspective for stroke prevention in AF has changed.[2] Coronary artery disease (CAD) is reported in 20%–40% of AF patients.[3] Over the lifetime course, 5–15% of AF patients are known to receive percutaneous coronary intervention (PCI), and 5–10% of PCI patients have concomitant AF.[4] Although OAC therapy is recommended to reduce the risk of ischemic stroke in patients with AF, dual antiplatelet therapy (DAPT) is recommended to reduce the risk of stent thrombosis in patients undergoing PCI. However, such a combination of antiplatelet agents and antithrombotic therapy with OAC may increase the risk of bleeding.

Recently, major clinical trials have reported the benefits of NOAC-based double antithrombotic therapy (DAT) over warfarin-based triple antithrombotic therapy (TAT) in AF patients with CAD undergoing PCI.[5-8] Hence, international guidelines have updated their recommendations based on these trials.[1)9-11]

Despite the rapidly evolving evidence-based strategies of antithrombotic therapy in AF patients with PCI, appropriate antithrombotic regimens are suboptimally prescribed in real-world practice, specifically in Asia. A previous study reported high rates of antiplatelet use and underutilization of OAC use in Korean AF patients after PCI.[12] One possible reason is that Asian patients with AF are known to have higher risks of stroke and bleeding than non-Asian patients.[13] Also, Asians are perceived to have a higher risk of bleeding for both antiplatelet agents and oral anticoagulants compared to non-Asians.[14] In the REDUAL-PCI trial, the Japanese subgroup had a higher rate of International Society on Thrombosis and Haemostasis major or clinically relevant non-major bleeding, while a lower rate of myocardial infarction (MI) or stent thrombosis than the overall population.[15] Therefore, there is the need to investigate the status of antithrombotic therapy in 'real-world' practice in Asian AF patients treated with PCI.

This study aimed to investigate how periprocedural antithrombotic regimens have been changed since the introduction of NOACs among Korean patients with AF undergoing PCI.

METHODS

This was a retrospective cross-sectional study using the claims database from the Health Insurance Review and Assessment (HIRA) during 2013–2018. The HIRA database provides medical claims information on the entire Korean population.[16] Its database comprises not only comprehensive claims information on prescriptions and procedures but also demographic data of each insured member. The HIRA database also has the disease status of each member encoded in the International Classification of Disease, Tenth Revision, Clinical Modification.[16] The data can be provided to researchers for academic purposes upon request. This study was approved by the Seoul National University Hospital Institutional Review Board (IRB) (IRB No. E-1911-052-1078), and the informed consent was waived by the review board due to the anonymized characteristics of the data. The study was conducted according to the ethical guidelines of the Declaration of Helsinki revised in 2013.

Study population and definitions

From the claims database, we identified the patients with AF undergoing PCI during 2013–2018. We used well-defined operational definitions for AF and PCI validated in a previous study.[16] AF was defined as having diagnostic codes of I48.0-48.4 or I48.9 during hospitalization or outpatient clinics. PCI was defined as having procedural codes of M6551, M6552, M6561-6564, M6571, and M6572. Study subjects were defined as those who had AF before PCI. Finally, we excluded patients with mitral stenosis (I50, I52, and I59) or prosthetic heart valves (Z952-Z954).

Using diagnostic codes, we defined several study variables of comorbidities, including hypertension, diabetes mellitus, dyslipidemia, peripheral arterial disease, ischemic stroke, systemic thromboembolism, intracranial hemorrhage, gastrointestinal bleeding, renal disease, and liver disease.[16] Their details are presented in **Supplementary Table 1**. To evaluate the risks of ischemic stroke and bleeding, we used the CHA_2DS_2-VASc and HAS-BLED scores, respectively.[17] HAS-BLED scores were calculated without international normalized ratio, and the amount of alcohol consumption as such information was not available in the HIRA database.[2] High risk of ischemic stroke or bleeding was defined as a CHA_2DS_2-VASc score ≥2 or HAS-BLED score ≥3, respectively.

Antithrombotic regimens

We examined the claims data for antithrombotic agents prescribed outpatient or inpatient for each patient. For antithrombotic agents, we included aspirin, clopidogrel, prasugrel, ticagrelor, warfarin, and NOAC (dabigatran, rivaroxaban, apixaban, and edoxaban). In Korea, NOAC was fully reimbursed after July 2015; thus, the prescription of NOAC has dramatically increased since then. The antithrombotic regimen was evaluated within 30 days after receiving PCI. The prescription period of interest was limited in the present study because this study aimed to examine the pattern of the management for antithrombotic therapy early after PCI.

We classified antithrombotic regimens according to the combination of prescribed agents into single antiplatelet therapy, DAPT, DAT (warfarin or NOAC-based), and TAT (warfarin or NOAC-based). Meanwhile, multiple combinations of antithrombotic prescriptions may be present in a patient within 30 days of PCI, in which case, the prescription comprising the maximum combination was selected.

Statistical analyses

The annual number of patients with AF undergoing PCI was investigated. The baseline characteristics, including age, sex, comorbidities, CHA_2DS_2-VASc, and HAS-BLED scores of the annual population, were evaluated. Data are presented as number (%) for dichotomous or categorical variables and as mean±standard deviation for continuous variables. The significance of a temporal trend of each study variable was analyzed using linear regression analysis over the study period. To investigate whether there were significant interactions between antithrombotic regimens and subgroups, we performed subgroup analyses for sex, high risks of ischemic stroke, and bleeding. We also performed a subgroup analysis for those hospitalized due to MI. MI was defined by having a primary diagnostic code of either I21 or I22 for hospitalization. This operational definition of MI has been validated to have a positive predictive value of 92% in our previous study.[18] To evaluate the independent predictors of favoring TAT over DAPT, we performed multivariate logistic regression analysis. Moreover, multivariate logistic regression analysis was performed to investigate the differences in the preference of TAT over DAPT across the scores of CHA_2DS_2-VASc or HAS-BLED. All analyses

were considered as statistically significant if the two-tailed p-value was less than 0.05. All statistical analyses were performed using the Statistical Analysis System (SAS) version 9.3 (SAS Institute Inc., Cary, NC, USA).

RESULTS

A total of 27,594 patients with AF undergoing PCI were identified using the claims database from 2013 to 2018. **Table 1** presents the baseline characteristics of the study population. The number of patients with AF undergoing PCI has generally increased from 3,913 in 2013 to 5,075 in 2018 (**Figure 1**). Moreover, the number of patients who had coronary stent implantation increased from 3,380 (86.4%) in 2013 to 4,432 (87.3%) in 2018, whereas the number of PCI procedures per patients has remained stationary (1.0±0.2 per patient). From 2013 to 2018, the mean age has increased from 69.4 to 71.3 years (p for trend <0.001), whereas the proportion of females decreased from 35.2% to 30.7% (p for trend <0.001).

Among the various comorbidities, the prevalence of dyslipidemia, congestive heart failure, and renal and liver diseases increased over the years, while that of MI, intracranial hemorrhage, and gastrointestinal bleeding decreased (p for trend <0.001 in all cases except intracranial

Table 1. Baseline characteristics of the study population

Years	2013	2014	2015	2016	2017	2018	p for trend
Demographics							
Patients with AF undergoing PCI	3,913	4,118	4,460	5,133	4,895	5,075	
Patients with AF undergoing PCI with stents	3,380	3,501	3,844	4,450	4,327	4,432	
PCI procedures	4,026	4,244	4,623	5,300	5,052	5,209	
PCI procedures with stent	3,432	3,567	3,928	4,548	4,424	4,507	
PCI procedures per patient	1.0±0.2	1.0±0.2	1.0±0.2	1.0±0.2	1.0±0.2	1.0±0.2	
Female	1,377 (35.2)	1,387 (33.7)	1,508 (33.8)	1,710 (33.3)	1,615 (33.0)	1,556 (30.7)	<0.001
Age (years)	69.4±10.5	69.9±10.8	70.2±10.6	70.6±10.4	71.0±10.2	71.3±10.1	<0.001
Age strata							
65–74 years	1,445 (36.9)	1,383 (33.6)	1,462 (32.8)	1,693 (33.0)	1,587 (32.4)	1,581 (31.2)	
≥75 years	1,344 (34.3)	1,566 (38.0)	1,750 (39.2)	2,058 (40.1)	2,036 (41.6)	2,234 (44.0)	
Comorbidities							
Hypertension	3,516 (89.9)	3,719 (90.3)	4,009 (89.9)	4,620 (90.0)	4,398 (89.8)	4,586 (90.4)	0.715
Diabetes mellitus	1,640 (41.9)	1,675 (40.7)	1,827 (41.0)	2,040 (39.7)	2,084 (42.6)	2,151 (42.4)	0.206
Dyslipidemia	3,216 (82.2)	3,520 (85.5)	3,912 (87.7)	4,479 (87.3)	4,342 (88.7)	4,513 (88.9)	<0.001
Congestive heart failure	1,543 (39.4)	1,810 (44.0)	2,033 (45.6)	2,525 (49.2)	2,631 (53.7)	2,735 (53.9)	<0.001
MI	1,565 (40.0)	1,740 (42.3)	1,930 (43.3)	2,252 (43.9)	1,873 (38.3)	1,878 (37.0)	<0.001
Peripheral arterial disease	1,051 (26.9)	1,111 (27.0)	1,217 (27.3)	1,514 (29.5)	1,505 (30.7)	1,630 (32.1)	<0.001
Ischemic stroke	488 (12.5)	512 (12.4)	476 (10.7)	541 (10.5)	507 (10.4)	565 (11.1)	0.993
Intracranial hemorrhage	49 (1.3)	27 (0.7)	22 (0.5)	35 (0.7)	26 (0.5)	35 (0.7)	0.009
Gastrointestinal bleeding	333 (8.5)	353 (8.6)	355 (8.0)	394 (7.7)	354 (7.2)	376 (7.4)	0.004
Renal disease	786 (20.1)	838 (20.3)	949 (21.3)	1,137 (22.2)	1,148 (23.5)	1,235 (24.3)	<0.001
Liver disease	1,379 (35.2)	1,491 (36.2)	1,748 (39.2)	2,070 (40.3)	2,015 (41.2)	2,164 (42.6)	<0.001
CHA_2DS_2-VASc score							
Mean	3.7±1.8	3.8±1.9	3.0±1.9	3.9±1.9	3.9±1.9	4.0±1.9	<0.001
Low (0–1)	427 (10.9)	430 (10.4)	461 (10.3)	487 (9.5)	439 (9.0)	434 (8.6)	
High (≥2)	3,486 (89.1)	3,688 (89.6)	3,999 (89.7)	4,646 (90.5)	4,456 (91.0)	4,641 (91.5)	
HAS-BLED score							
Mean	3.3±1.1	3.4±1.1	3.4±1.0	3.4±1.0	3.4±1.0	3.5±1.0	<0.001
Low (0–1)	112 (2.9)	132 (3.2)	103 (2.3)	127 (2.5)	105 (2.1)	106 (2.1)	
Intermediate (2)	669 (17.1)	645 (15.7)	713 (16.0)	716 (13.9)	701 (14.3)	659 (13.0)	
High (≥3)	3,132 (80.0)	3,341 (81.1)	3,644 (81.7)	4,290 (83.6)	4,089 (83.5)	4,310 (84.9)	

Data are presented as number (%) or mean±standard deviation.
AF = atrial fibrillation; MI = myocardial infarction; PCI = percutaneous coronary intervention.

Figure 1. Temporal trends of patients with AF undergoing PCI after introduction of NOAC.
AF = atrial fibrillation; NOAC = non-vitamin K oral anticoagulant; PCI = percutaneous coronary intervention.

hemorrhage [p for trend =0.009] and gastrointestinal bleeding [p for trend =0.004]). Overall, both the CHA$_2$DS$_2$-VASc and HAS-BLED scores increased from 3.7±1.8 and 3.3±1.1 in 2013 to 4.0±1.9 and 3.5±1.0 in 2018, respectively (p for trend <0.001 for both scores). During the study period, patients with CHA$_2$DS$_2$-VASc scores ≥2 increased from 89.1% to 91.5% and those with HAS-BLED scores ≥3 increased from 80.0% to 84.9% (**Figure 1**).

Trends in antithrombotic prescriptions among patients with atrial fibrillation undergoing percutaneous coronary intervention

Table 2 presents detailed data for the annual proportions of each antithrombotic prescription among patients with AF undergoing PCI. During the study period, DAPT significantly decreased from 2,815 (71.9%) to 2,525 (49.8%), whereas TAT increased from 995 (25.4%) to 2,335 (46.0%) (both p for trend <0.001) (**Figure 2**). Such an increase in TAT was dominated by NOAC-based regimens (from 39 [1.0%] to 2027 [39.9%]). In contrast, warfarin-based regimens diminished from 956 (24.4%) to 308 (6.1%). For NOAC-based regimens, we evaluated the annual proportions of both regular- and reduced-dose NOAC regimens. The prescription of reduced-dose NOACs was increased from 57.5% to 81.4% from 2013 to 2018

Table 2. Temporal trends of antithrombotic regimens among patients with AF undergoing PCI

Year	2013	2014	2015	2016	2017	2018	p for trend
Patients with AF undergoing PCI	3,913	4,118	4,460	5,133	4,895	5,075	
Triple therapy (NOAC)	39 (1.0)	29 (0.7)	358 (8.0)	1,180 (23.0)	1,498 (30.6)	2,027 (39.9)	<0.001
Triple therapy (warfarin)	956 (24.4)	1,031 (25.0)	835 (18.7)	603 (11.7)	405 (8.3)	308 (6.1)	<0.001
Double therapy (NOAC)	1 (0.0)	1 (0.0)	10 (0.2)	48 (0.9)	62 (1.3)	115 (2.3)	<0.001
Double therapy (warfarin)	25 (0.6)	29 (0.7)	30 (0.7)	10 (0.2)	14 (0.3)	10 (0.2)	<0.001
DAPT	2,815 (71.9)	2,933 (71.2)	3,144 (70.5)	3,200 (62.3)	2,809 (57.4)	2,525 (49.8)	<0.001
SAPT	50 (1.3)	70 (1.7)	51 (1.1)	53 (1.0)	71 (1.5)	58 (1.1)	0.284
No antithrombotic therapy	27 (0.7)	25 (0.6)	29 (0.7)	35 (0.7)	26 (0.5)	28 (0.6)	0.359
Patients with NOAC-based regimens	40	30	368	1,228	1,560	2,142	
Patients with regular-dose NOAC	17 (42.5)	15 (50)	113 (30.7)	246 (20)	277 (17.8)	398 (18.6)	<0.001
Patients with reduced-dose NOAC	23 (57.5)	15 (50.0)	255 (69.3)	982 (80.0)	1,283 (82.2)	1,744 (81.4)	<0.001

Data are presented as number (%).
AF = atrial fibrillation; DAPT = dual antiplatelet therapy; NOAC = non-vitamin K antagonist oral anticoagulant; PCI = percutaneous coronary intervention; SAPT = single antiplatelet therapy.

Figure 2. Temporal trends of antithrombotic regimens in patients with AF undergoing PCI after introduction of NOAC.
AF = atrial fibrillation; DAPT = dual antiplatelet therapy; NOAC = non-vitamin K oral anticoagulant; PCI = percutaneous coronary intervention.

(**Table 2**). Among the different regimens, DAPT was the most common, regardless of the period in both sexes, in those with CHA_2DS_2-VASc scores ≥2, and in those with HAS-BLED scores ≥3 (**Table 3**).

The results of subgroup analysis for patients hospitalized due to MI are presented in **Supplementary Table 2**. Generally, the temporal trends of antithrombotic regimens in those

Table 3. Subgroup analyses for the temporal trends of antithrombotic regimens

Year	2013	2014	2015	2016	2017	2018	p for trend
Male	2,536	2,731	2,952	3,423	3,280	3,519	
Triple therapy (NOAC)	23 (0.9)	15 (0.5)	221 (7.5)	758 (22.1)	1,003 (30.6)	1,384 (39.3)	<0.001
Triple therapy (warfarin)	630 (24.8)	648 (23.7)	561 (19.0)	410 (12.0)	288 (8.8)	232 (6.6)	<0.001
Double therapy (NOAC)	1 (0.0)	1 (0.0)	6 (0.2)	29 (0.8)	49 (1.5)	74 (2.1)	<0.001
Double therapy (warfarin)	14 (0.6)	20 (0.7)	22 (0.7)	7 (0.2)	11 (0.3)	8 (0.2)	<0.001
DAPT	1,817 (71.6)	1,982 (72.6)	2,083 (70.6)	2,152 (62.9)	1,865 (56.9)	1,754 (49.8)	<0.001
SAPT	32 (1.3)	47 (1.7)	39 (1.3)	38 (1.1)	40 (1.2)	45 (1.3)	0.350
No antithrombotic therapy	19 (0.7)	18 (0.7)	20 (0.7)	26 (0.8)	18 (0.5)	20 (0.6)	0.343
Female	1,377	1,387	1,508	1,710	1,615	1,556	
Triple therapy (NOAC)	16 (1.2)	14 (1.0)	137 (9.1)	422 (24.7)	495 (30.7)	643 (41.3)	<0.001
Triple therapy (warfarin)	326 (23.7)	383 (27.6)	274 (18.2)	193 (11.3)	117 (7.2)	76 (4.9)	<0.001
Double therapy (NOAC)	0 (0)	0 (0)	4 (0.3)	19 (1.1)	13 (0.8)	41 (2.6)	<0.001
Double therapy (warfarin)	11 (0.8)	9 (0.6)	8 (0.5)	3 (0.2)	3 (0.2)	2 (0.1)	<0.001
DAPT	998 (72.5)	951 (68.6)	1,061 (70.4)	1,048 (61.3)	944 (58.5)	771 (49.6)	<0.001
SAPT	18 (1.3)	23 (1.7)	12 (0.8)	15 (0.9)	31 (1.9)	13 (0.8)	0.578
No antithrombotic therapy	8 (0.6)	7 (0.5)	9 (0.6)	9 (0.5)	8 (0.5)	8 (0.5)	0.781
Patients with high risk of systemic thromboembolism*	3,486	3,688	3,999	4,646	4,456	4,641	
Triple therapy (NOAC)	38 (1.1)	28 (0.8)	337 (8.4)	1,115 (24.0)	1,412 (31.7)	1,904 (41.0)	<0.001
Triple therapy (warfarin)	870 (25.0)	952 (25.8)	775 (19.4)	550 (11.8)	371 (8.3)	284 (6.1)	<0.001
Double therapy (NOAC)	1 (0.0)	1 (0.0)	9 (0.2)	45 (1.0)	54 (1.2)	107 (2.3)	<0.001
Double therapy (warfarin)	21 (0.6)	24 (0.7)	26 (0.7)	10 (0.2)	11 (0.2)	10 (0.2)	<0.001
DAPT	2,489 (71.4)	2,598 (70.4)	2,783 (69.6)	2,836 (61.0)	2,509 (56.3)	2,254 (48.6)	<0.001
SAPT	43 (1.2)	63 (1.7)	40 (1.0)	52 (1.1)	68 (1.5)	54 (1.2)	0.617
No antithrombotic therapy	24 (0.7)	22 (0.6)	26 (0.7)	34 (0.7)	22 (0.5)	24 (0.5)	0.276
Patients with high risk of bleeding†	3,132	3,341	3,644	4,290	4,089	4,310	
Triple therapy (NOAC)	36 (1.1)	27 (0.8)	313 (8.6)	1,040 (24.2)	1,313 (32.1)	1,778 (41.3)	<0.001
Triple therapy (warfarin)	802 (25.6)	875 (26.2)	723 (19.8)	508 (11.8)	348 (8.5)	256 (5.9)	<0.001
Double therapy (NOAC)	1 (0.0)	0 (0)	10 (0.3)	46 (1.1)	52 (1.3)	102 (2.4)	<0.001
Double therapy (warfarin)	21 (0.7)	27 (0.8)	24 (0.7)	9 (0.2)	12 (0.3)	8 (0.2)	<0.001
DAPT	2,207 (70.5)	2,331 (69.8)	2,507 (68.8)	2,606 (60.7)	2,278 (55.7)	2,091 (48.5)	<0.001
SAPT	43 (1.4)	59 (1.8)	41 (1.1)	48 (1.1)	61 (1.5)	50 (1.2)	0.243
No antithrombotic therapy	22 (0.7)	22 (0.7)	23 (0.6)	29 (0.7)	17 (0.4)	21 (0.5)	0.092

Data are presented as number (%).
DAPT = dual antiplatelet therapy; NOAC = non-vitamin K antagonist oral anticoagulant; SAPT = single antiplatelet therapy.
*Patients with CHA_2DS_2-VASc score ≥2; †Patients with HAS-BLED score ≥3.

with or without MI were similar. However, compared to patients without MI, those with MI had a higher proportion of DAPT and low proportions of TAT and DAT consistently over the study period. This finding may suggest that, if a patient with AF is hospitalized due to acute coronary syndrome, then the patient may have more attention to the management for acute coronary syndrome than for AF.

We also evaluated the annual trends of each NOAC type and $P2Y_{12}$ inhibitor (**Supplementary Tables 3** and **4**). From 2013 to 2018, dabigatran uses decreased from 75.6% to 7.9%, while apixaban and edoxaban increased to 34.3% and 24.2%, respectively. In summary, both rivaroxaban and apixaban are the two most preferred NOACs. For $P2Y_{12}$ inhibitors, clopidogrel was the most preferred choice, while prasugrel was the least used. From 2013 to 2018, the proportion of ticagrelor use has been substantially increased, although the combination of NOAC and ticagrelor was not recommended in the guidelines.[11]

Predictors of favoring triple antithrombotic therapy over dual antiplatelet therapy

Multivariate logistic regression analysis was performed to evaluate the predictors favoring TAT over DAPT. Among the covariates, the most significant predictor of TAT was age ≥75

Figure 3. Multivariate logistic regression analysis for factors associated with prescriptions of triple therapy.
CI = confidence interval; DAPT = dual antiplatelet therapy; OR = odds ratio; TIA = transient ischemic attack.

years (odds ratio [OR], 1.890; 95% confidence interval [CI], 1.576–2.267). Other significant predictors included age of 65–74 years, congestive heart failure, CHA$_2$DS$_2$-VASc scores ≥2, hypertension, and systemic thromboembolic events (**Figure 3**). Factors favoring DAPT over TAT included female sex, peripheral arterial disease, MI, dyslipidemia, renal disease, and intracranial hemorrhage. Among those factors, intracranial hemorrhage was the most potent predictor favoring DAPT (OR, 0.375; 95% CI, 0.170–0.827). Presence of diabetes mellitus and high bleeding risk (HAS-BLED score ≥3) did not show a significant preference for either of the 2 regimens.

Impacts of thromboembolic or bleeding risks on antithrombotic prescriptions
Taking the patients with low-risk CHA$_2$DS$_2$-VASc score (0 in males and 1 in females) as the reference, those with higher scores showed a non-significant preference for TAT over DAPT (**Figure 4**). For the case of the risk of bleeding, compared to the patients with a HAS-BLED score of 0 or 1, those with higher scores showed a non-significant preference of DAPT over TAT.

DISCUSSION

This study investigated the trends of periprocedural antithrombotic therapy in patients with AF undergoing PCI using the claims database in the NOAC era. Our principal findings are as follows: (i) the number of Korean patients with AF undergoing PCI has been substantially increased after the introduction of NOACs in 2013; (ii) the risk profile for both ischemic stroke and bleeding of these patients has been increasing annually; (iii) periprocedural antithrombotic regimen has shifted from DAPT-based to NOAC-based TAT, but DAPT was still the most favored antithrombotic therapy; (iv) the predictors of underuse of TAT were intracranial hemorrhage, renal disease, dyslipidemia, MI, peripheral arterial disease, and

Figure 4. The impact of CHA$_2$DS$_2$-VASc or HAS-BLED scores on the preference of antithrombotic regimens.
Multivariate logistic regression analysis based on the study population of 2018. CHA$_2$DS$_2$-VASc score of 0 and HAS-BLED score of 1 served as the reference in each analysis, respectively.
CI = confidence interval; DAPT = dual antiplatelet therapy; OR = odds ratio.

female sex; and (v) TAT or DAPT was seemed to be preferred in the case of a high risk of ischemic stroke or bleeding, respectively, although this trend was not statistically significant.

This study has the following main strengths: it evaluated AF-PCI patients on a national scale and, to the best of our knowledge, included the largest number of patients. The management of AF-PCI patients has been rapidly evolving in recent years as NOACs were introduced, but detailed temporal trend data on real-world clinical practice have been relatively rare. This study illustrates a clear gap between guideline recommendations and real-world clinical practice.

Before 2016, studies on antithrombotic therapy in AF-PCI patients had investigated the combination therapy of warfarin and antiplatelet drugs. The WOEST trial[19] compared bleeding events 1 year after PCI between the TAT group treated with warfarin, aspirin, and clopidogrel and the DAT group treated with warfarin and clopidogrel. This trial found that compared to TAT, DAT significantly reduced the risk of bleeding without increasing the risk of thrombotic events. A Danish nationwide cohort study reported that warfarin-based DAT showed a lower risk of bleeding than TAT, without increasing the risk of ischemic events.[20]

Since 2016, studies have been focused on using combination therapy of NOAC and antiplatelet drugs. Clinical trials, including PIONEER AF-PCI,[5] RE-DUAL PCI,[6] AUGUSTUS,[7] and ENTRUST-AF-PCI,[8] studied DAT based on rivaroxaban, dabigatran, apixaban, and edoxaban, respectively. Although the study designs were different, NOAC-based DAT was associated with a lower risk of bleeding without increasing the risk of ischemic events compared to warfarin-based TAT.[21,22] Accordingly, various international guidelines have been updated.[1,9-11]

All the guidelines largely advocate approaches that have more similarities than differences. First, a thorough evaluation of the risks of the ischemic events and bleeding is needed before the decision of an antithrombotic regimen. Second, NOACs are generally preferred to warfarin if anticoagulant therapy is required among AF patients with PCI. Third, in the periprocedural period, the combination of aspirin and clopidogrel is usually recommended, regardless of treatment strategy, provided that the risk of bleeding is not significantly high. Therefore, when AF patients requiring OAC receive PCI, both North American and European guidelines recommend NOAC-based TAT during the periprocedural period. Depending on

the balance between the risk of ischemic events and bleeding, the period of TAT needed to be adjusted from 1 to 6 months individually. Afterward, NOAC-based DAT up to 12 months followed by NOAC monotherapy is recommended.[21]

In this study, the proportion of patients receiving DAT was significantly small (<3%), and most received TAT or DAPT. We investigated which factors favored TAT or DAPT. Importantly, a high risk of bleeding (HAS-BLED score ≥3) did not have a significant association with the treatment choice, although a high HAS-BLED score should be used to identify and mitigate reversible bleeding risk factors and to identify high-risk patients for early review and follow-up.[23] In contrast, a high risk of thromboembolism (CHA_2DS_2-VASc scores ≥2) was associated with TAT (**Figure 3**). The most important factor favoring DAPT was a history of intracranial hemorrhage, which was presumed to be due to the recurrence of hemorrhage, although DAPT has a similar risk of ICH as OAC.[24] We found that DAPT was preferred if the patient had intracranial hemorrhage, renal disease, dyslipidemia, or vascular diseases, such as MI and peripheral arterial disease. We assume that more attention tends to be focused on the management of MI rather than stroke prevention in patients with AF who receive PCI for acute MI. Briefly, stroke risk factors favored TAT, whereas the covariates specific to the risk of bleeding favored DAPT. The covariates common to the risks of both stroke and bleeding favored TAT.

Non-Asians have a lower risk of major bleeding on administration of oral anticoagulants than Asians.[25] Even in the Western populations, OACs in AF patients after PCI are underprescribed. In the CRUSADE registry of 1,648 patients with non-ST segment elevation MI and AF, only 27% were prescribed TAT, whereas 73% were prescribed DAPT at discharge.[26] Such a suboptimal usage of OACs is considered to be affected by concerns of bleeding when prescribing TAT, specifically in elderly individuals. In another Danish study analyzing 12,165 AF patients with PCI from 2001 to 2009, the proportion of TAT was only accounted for in 15.6%.[27]

The real-world data of non-Asians have been reported on antithrombotic therapy in patients with AF undergoing PCI.[28] In the Danish nationwide registries from 2011 to 2017, NOAC with DAPT had a lower risk of bleeding than warfarin with DAPT, with a comparable risk of thromboembolism. Another Danish nationwide registries study from 2011 to 2016 found that the proportion of TAT had been increased (43% in 2011 to 60% in 2016), while that of DAT decreased.[29] After the introduction of NOACs, warfarin-based therapy decreased, while NOAC-based therapy increased. Although DAPT was the most common antithrombotic regimen, this study did not provide the temporal trend of DAPT during the study period.

Consistent with the Danish study,[28] we found that NOAC-based therapy outpaced warfarin-based therapy from 2016, which was related to changes in the reimbursement criteria in Korea. Moreover, prescriptions of TAT increased, and those of DAPT decreased, but DAPT was the most preferred antithrombotic regimen in patients with AF undergoing PCI. Based on these studies, stroke prevention using OAC remains underutilized in AF patients with PCI among both Asian and non-Asian populations.

In Asia, OACs are more suboptimally prescribed in patients with AF undergoing PCI. One study investigated the temporal trends of antithrombotic therapy in Korean AF-PCI patients during 2006 and 2015, whereby the proportion of TAT increased from 22.7% to 38.2%, but DAPT still comprised the largest proportion at 60.3%.[12] However, there is a caveat that this

study examined the antithrombotic regimen over the entire year of PCI, unlike the current study, which investigated only the regimen during the periprocedural period (i.e., within 30 days after PCI). One real-world study from Taiwan also showed that DAPT was the most common regimen (72.0%), while TAT was used in only 15.0% of patients.[30] Thus, despite several international guidelines that recommend NOAC-based TAT during the periprocedural period for AF-PCI patients, adherence to guidelines using OAC is still suboptimal despite the introduction of NOACs. The underuse of OACs appears to be due to concerns that adding warfarin to DAPT may increase the risk of bleeding, while the benefit of reducing thromboembolism is unclear among Asians. Since NOACs are rapidly replacing warfarin with better efficacy and safety for stroke prevention in patients with AF, there is the need to reconsider OAC-based therapy over DAPT in line with the recent evidences and guidelines. Meanwhile, we also found that most of NOACs were prescribed as reduced-dose (81.4% of total NOAC-based regimens in 2018) (**Table 2**). This pattern might reflect the concerns of bleeding for using triple therapy with regular-dose NOACs.

This study shares the limitations of other studies based on claims data. First, there may be a discrepancy between the prescriptions and the medications actually consumed by patients, and such a difference cannot be further evaluated in this study. For a given individual, the antithrombotic prescription chosen in this study was the one with the maximum combination of antiplatelet or anticoagulant drugs within 30 days after the PCI. Therefore, if OACs were prescribed prior to PCI, DAT or TAT may have been underestimated. Second, since this study used claims data, which lack detailed clinical information or medical records, we could not investigate the reasons for patients with DAPT not being prescribed OACs. Third, because this study is a cross-sectional observational study, it is not possible to confirm how the clinical outcome differs for each regimen. Fourth, the operational definition of the maximum combination of antithrombotic therapy might influence on the proportion of DAT. We analyzed the maximum combination of antithrombotic drugs prescribed within 30 days after PCI. Those who had changed from TAT to DAT within 30 days after PCI were regarded as the TAT group. Therefore, there is a chance that TAT may be over-estimated, whereas DAT might be under-estimated. If we consider a more extended period after one month from PCI, a higher proportion of DAT would be expected. This study focused on the treatment during the periprocedural period, and long-term therapy should be analyzed in a follow-up study. Lastly, it is challenging to estimate the duration of TAT accurately because of some differences in the date of claiming the reimbursement and prescription date.

After the introduction of NOACs for stroke prevention in AF, early periprocedural antithrombotic regimens in Korean patients with AF undergoing PCI have shifted toward less DAPT and more TAT. NOACs are increasingly used when OAC is prescribed; however, DAPT was still the most common regimen during the periprocedural period.

SUPPLEMENTARY MATERIALS

Supplementary Table 1
Operational definitions of covariates and study outcomes

Click here to view

Supplementary Table 2
Subgroup analysis for patients hospitalized due to MI

Click here to view

Supplementary Table 3
Temporal trends of NOAC prescriptions by NOAC types

Click here to view

Supplementary Table 4
Temporal trends of P2Y$_{12}$ inhibitor prescriptions

Click here to view

REFERENCES

1. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report. *Chest* 2018;154:1121-201.
   PUBMED | **CROSSREF**

2. Lee SR, Choi EK, Kwon S, et al. Effectiveness and safety of contemporary oral anticoagulants among Asians with nonvalvular atrial fibrillation. *Stroke* 2019;50:2245-9.
   PUBMED | **CROSSREF**

3. Michniewicz E, Mlodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J. Patients with atrial fibrillation and coronary artery disease - double trouble. *Adv Med Sci* 2018;63:30-5.
   PUBMED | **CROSSREF**

4. Choi HI, Ahn JM, Kang SH, et al. Prevalence, management, and long-term (6-year) outcomes of atrial fibrillation among patients receiving drug-eluting coronary stents. *JACC Cardiovasc Interv* 2017;10:1075-85.
   PUBMED | **CROSSREF**

5. Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. *N Engl J Med* 2016;375:2423-34.
   PUBMED | **CROSSREF**

6. Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. *N Engl J Med* 2017;377:1513-24.
   PUBMED | **CROSSREF**

7. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. *N Engl J Med* 2019;380:1509-24.
   PUBMED | **CROSSREF**

8. Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. *Lancet* 2019;394:1335-43.
   PUBMED | **CROSSREF**

9. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol* 2019;74:104-32.
   PUBMED | **CROSSREF**

10. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 2019;40:87-165.
    PUBMED | **CROSSREF**

11. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). *Eur Heart J*. 2020 [Epub ahead of print].
    PUBMED | **CROSSREF**

12. Park J, Choi EK, Han KD, et al. Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: a nationwide Korean population-based study. *PLoS One* 2019;14:e0209593.
    PUBMED | **CROSSREF**

13. Li YG, Lee SR, Choi EK, Lip GY. Stroke prevention in atrial fibrillation: focus on Asian patients. *Korean Circ J* 2018;48:665-84.
    PUBMED | **CROSSREF**

14. Kim HK, Tantry US, Smith SC Jr, et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. *Thromb Haemost.* 2020 [Epub ahead of print].
    PUBMED | **CROSSREF**

15. Ako J, Okumura K, Nakao K, et al. Dual anti-thrombotic therapy with dabigatran after percutaneous coronary intervention in atrial fibrillation - Japanese and East-Asian Subgroup Analysis of the RE-DUAL PCI Trial. *Circ J* 2019;83:327-33.
    PUBMED | **CROSSREF**

16. Choi EK. Cardiovascular research using the Korean National Health Information Database. *Korean Circ J* 2020;50:754-72.
    PUBMED | **CROSSREF**

17. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest* 2010;138:1093-100.
    PUBMED | **CROSSREF**

18. Park J, Kwon S, Choi EK, et al. Validation of diagnostic codes of major clinical outcomes in a National Health Insurance database. *Int J Arrhythm.* 2019;20:5.
    CROSSREF

19. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. *Lancet* 2013;381:1107-15.
    PUBMED | **CROSSREF**

20. Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. *Circulation* 2012;126:1185-93.
    PUBMED | **CROSSREF**

21. Capodanno D, Huber K, Mehran R, et al. Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC State-of-the-Art Review. *J Am Coll Cardiol* 2019;74:83-99.
    PUBMED | **CROSSREF**

22. Lopes RD, Hong H, Harskamp RE, et al. Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials. *JAMA Cardiol* 2019;4:747-55.
    PUBMED | **CROSSREF**

23. Guo Y, Lane DA, Chen Y, Lip GYH; mAF-App II Trial Investigators. Regular bleeding risk assessment associated with reduction in bleeding outcomes: the mAFA-II Randomized Trial. *Am J Med* 2020;133:1195-1202.e2.
    PUBMED | **CROSSREF**

24. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. *Lancet* 2006;367:1903-12.
    PUBMED | **CROSSREF**

25. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. *J Am Coll Cardiol* 2007;50:309-15.
    PUBMED | **CROSSREF**

26. Fosbol EL, Wang TY, Li S, et al. Warfarin use among older atrial fibrillation patients with non-ST-segment elevation myocardial infarction managed with coronary stenting and dual antiplatelet therapy. *Am Heart J* 2013;166:864-70.
    PUBMED | **CROSSREF**

27. Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. *J Am Coll Cardiol* 2013;62:981-9.
    PUBMED | **CROSSREF**

28. Sindet-Pedersen C, Lamberts M, Staerk L, et al. Combining oral anticoagulants with platelet inhibitors in patients with atrial fibrillation and coronary disease. *J Am Coll Cardiol* 2018;72:1790-800.
    PUBMED | **CROSSREF**

29. Sindet-Pedersen C, Staerk L, Lamberts M, et al. Use of oral anticoagulants in combination with antiplatelet(s) in atrial fibrillation. *Heart* 2018;104:912-20.
    PUBMED | **CROSSREF**

30. Wang YH, Kao HL, Wang CC, Lin SY, Lin FJ. Comparative effectiveness and safety of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome or percutaneous coronary intervention. *Acta Cardiol Sin* 2019;35:508-21.
    PUBMED | **CROSSREF**